There are three published GWAS to date that have identified eight different loci associated with glioma risk [1], [2], [3], including variants annotating key genes in glioma progression, such as the epidermal growth factor receptor (EGFR), and the tumor suppressor gene CDKN2A (alias p14, p16, and ARF). This evidence concerns the gene CDKN2A and central nervous system cancer.